have suggested that the evaluation of KRT7 mRNA expression in circulating tumor cells (CTCs) among patients who have been diagnosed with urothelial bladder cancer prior to undergoing radical cystectomy (RC) or bladder removal surgery is a crucial tool for predicting patient prognosis and identifying potential candidates for systemic treatment (19, 20). This evidence concerns the gene KRT7 and bladder transitional cell carcinoma.